Project Grant R01CA306944
- Federal Grant Award Summary Case Western Reserve University received a $147,486 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with a completion date of May 31, 2027. The award supports the development of a pathologically interpretable computational imaging predictor designed to identify patients with locally advanced rectal cancer who exhibit complete response (CR) to total neoadjuvant therapy (TNT)...
- Federal Grant Award Summary Case Western Reserve University received a $109,076 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded January 10, 2026, with completion targeted for September 9, 2028. The project, titled "MR Fingerprinting for Characterization and Prediction of Glioblastoma Infiltration," focuses on developing and validating magnetic resonance fingerprinting (MRF) technology to improve glioblastoma (GBM)...
- Federal Grant Award Summary Case Western Reserve University's Office of Research Administration, in affiliation with University Hospitals of Cleveland, received a $510,650 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on September 1, 2025, with completion targeted for August 31, 2030. The award supports research into biological factors driving clinical outcomes in human papillomavirus–positive (HPV+) oropharyngeal squamous cell...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $487,468 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, effective September 1, 2025 through August 31, 2030. This five-year research initiative focuses on understanding palmitoylation dynamics and their role in melanoma lung metastasis progression. The project investigates how the palmitoyl-transferase enzyme...
- Federal Project Grant Award Summary The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $713,601 (awarded August 1, 2025; completion date July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to investigate how homologous recombination (HR) DNA repair pathway mutations influence tumor immunity and immunotherapy efficacy. The research will characterize the mechanisms by which HR defects affect...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $144,193 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 4, 2025, with a completion date of August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath to serve as a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, leveraging her expertise in mouse models, molecular biology, and imaging techniques...
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Dayton a $451,131 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 9, 2025, with a completion date of May 31, 2028. Led by Principal Investigators Shawn Swavey (Department of Chemistry) and Kristen Krupa (Department of Chemical and Materials Engineering), this project will develop endoplasmic reticulum (ER)-targeting boron dipyrrin (BODIPY) fluorescent imaging agents...
- Federal Grant Award Summary The National Cancer Institute awarded a $684,107 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on August 18, 2025, with completion anticipated by July 31, 2030. The grant funds research integrating circulating tumor cell (CTC) biomarkers with nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $700,838 to the University of California, San Francisco under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a five-year Project Grant spanning April 1, 2026 through March 31, 2031. The award supports development and optimization of advanced magnetic resonance (MR) imaging and radiation therapy planning technologies to improve treatment outcomes for patients with primary and secondary liver tumors....
Case Western Reserve University received a $630,108 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 13, 2026, with completion targeted for February 28, 2030. The grant funds research to develop and validate theranostic approaches for breast cancer treatment by leveraging the combined diagnostic and therapeutic properties of AKRO-6QC, a cysteine protease-activated agent. The research deliverables include optimization of AKRO-6QC for fluorescence image-guided surgery (FIGS) applications and photothermal therapy (PTT), with the ultimate objective of developing an integrated FIGS/PTT approach that enhances surgical precision, induces robust immune responses, and prevents tumor recurrence and metastasis in breast cancer patients. The research encompasses three specific aims culminating in preclinical efficacy demonstration using immunocompetent syngeneic mouse models of breast cancer. Key deliverables include assessments of AKRO-6QC-targeted FIGS/PTT efficacy in extending animal survival, delaying tumor recurrence, and preventing local and distant metastasis using the 4T1/LUC transfected breast cancer cell line in female BALB/c mice, as well as mechanistic investigation of the relationship between the combined therapeutic approach and immune response, with particular focus on myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). The research will be conducted at Case Western Reserve University's Cleveland, Ohio facilities under the Office of Research Administration in affiliation with University Hospitals of Cleveland.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $630.1k | 3/13/26 |